An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)
Sponsor: ADMA Biologics, Inc.
Listed as NCT05070455, this PHASE4 trial focuses on Primary Immune Deficiency and remains ongoing. Sponsored by ADMA Biologics, Inc., it has been updated 6 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Oct 2024 — Present [monthly]
Unknown PHASE4
Status: Recruiting → Unknown
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Sep 2022 — Jul 2024 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Mar 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE4
▶ Show 1 earlier version
-
Nov 2021 — Mar 2022 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ADMA Biologics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .